COME TI POSSIAMO AIUTARE?

Centralino
095 7339000

Se hai bisogno di maggiori informazioni contattaci telefonicamente

Prenotazioni
095 7339000

Prenota una visita in privato o con assicurazione telefonicamente, oppure direttamente online

Contabilità
095 73390119
Direzione sanitaria
095 73390203
Direzione amministrativa
095 73390668
Ufficio stampa e comunicazione
095 73390764

Prof. Paolo Vigneri

Prenota una visita
  • Area Medica
    Unità Operativa di Oncologia Medica Universitaria
  • Ruolo
    Responsabile Unità Operativa di Oncologia Medica Universitaria

Io in Humanitas

Unità
Oncologia Medica Universitaria
Ruolo in Ospedale
Responsabile Unità Operativa di Oncologia Medica Universitaria

Esperienze precedenti

Ultima esperienza lavorativa
Dal 2014 al 2023
Professore Associato di Oncologia Medica
Università di Catania
Dipartimento di Scienze Mediche e Pediatriche

Penultima esperienza lavorativa
Dal 2013 al 2014
Ricercatore Universitario
Università di Catania
Dipartimento di Scienze Mediche e Pediatriche

Formazione

Laurea
Medicina e Chirurgia
Anno di laurea: 1994
Università degli studi di Catania

Specializzazione
Oncologia
Anno: 1998
Università di Milano – Istituto Nazionale Tumori

Fellowship
Anno: 2001
Moores Cancer Center – University of California, San Diego

Dottorato di Ricerca in Oncologia
Anno: 2003
Università “Magna Graecia” – Catanzaro

Pubblicazioni ed attività scientifica

Gentile D, Martorana F, Karakatsanis A, Caruso F, Caruso M, Castiglione G, Di Grazia A, Pane F, Rizzo A, Vigneri P, Tinterri C, Catanuto G.

Predictors of mastectomy in breast cancer patients with complete remission of primary tumor after neoadjuvant therapy: A retrospective study.

Eur J Surg Oncol. 2024 Oct 2; 50(12):108732. doi: 10.1016/j.ejso.2024.108732. PMID: 39362047

  • Di Grazia G, Conti C, Nucera S, Motta G, Martorana F, Stella S, Massimino M, Giuliano M, Vigneri P.

REThinking the role of the RET oncogene in breast cancer.

Front Oncol. 2024 Aug 1; 14:1427228. doi: 10.3389/fonc.2024.1427228. PMID: 39211557

  • Schettini F, Gattazzo F, Nucera S, Rubio Garcia E, López-Aladid R, Morelli L, Fontana A, Vigneri P, Casals-Pascual C, Iebba V, Generali D.

Navigating the complex relationship between human gut microbiota and breast cancer: Physiopathological, prognostic and therapeutic implications.

Cancer Treat Rev. 2024 Aug 17; 130:102816. doi: 10.1016/j.ctrv.2024.102816. PMID: 39182440

  • Helmijr J, Motta G, Jongbloed L, de Weerd V, van Bergen L, Verschoor N, Stella S, Beaufort C, Vigneri P, Martens JWM, Wilting SM, Jansen MPHM.

A Multiplex Assay for Fast PIK3CA Hotspot Mutation Characterization in a Single Specimen by 3-Color Digital PCR Analysis.

J Appl Lab Med. 2024 Sep 3; 9(5):913-925. doi: 10.1093/jalm/jfae064. PMID: 39012846

  • Piazza D, Martorana F, Curaba A, Sambataro D, Valerio MR, Firenze A, Pecorino B, Scollo P, Chiantera V, Scibilia G, Vigneri P, Gebbia V, Scandurra G.

The Consistency and Quality of ChatGPT Responses Compared to Clinical Guidelines for Ovarian Cancer: A Delphi Approach.

Curr Oncol. 2024 May 14; 31(5):2796-2804. doi: 10.3390/curroncol31050212. PMID: 38785493

  • Broggi G, Massimino M, Failla M, Filetti V, Rapisarda V, Ledda C, Lombardo C, Loreto C, Vigneri P, Caltabiano R.

Concordance between CDKN2A homozygous deletion and MTAP immunohistochemical loss in fluoroedenite-induced pleural mesothelioma: an immunohistochemical and molecular study on a single-institution series.

Pathol Res Pract. 2024 Jul; 259:155350. doi: 10.1016/j.prp.2024.155350. PMID: 38781764

  • Martorana F, Sanò MV, Valerio MR, Fogli S, Vigneri P, Danesi R, Gebbia V.

Abemaciclib pharmacology and interactions in the treatment of HR+/HER2- breast cancer: a critical review.

Ther Adv Drug Saf. 2024 Apr 25; 15:20420986231224214. doi: 10.1177/20420986231224214. PMID: 38665218

  • Marino A, Pavone G, Martorana F, Fisicaro V, Motta L, Spampinato S, Celesia BM, Cacopardo B, Vigneri P, Nunnari G.

Navigating the Nexus: HIV and Breast Cancer-A Critical Review.

Int J Mol Sci. 2024 Mar 12; 25(6):3222. doi: 10.3390/ijms25063222. PMID: 38542195

  • Martorana F, Scandurra G, Valerio MR, Cufari S, Vigneri P, Sanò MV, Scibilia G, Scollo P, Gebbia V.

A review and metanalysis of metronomic oral single-agent cyclophosphamide for treating advanced ovarian carcinoma in the era of precision medicine.

J Oncol Pharm Pract. 2024 Jan; 30(1):173-181. doi: 10.1177/10781552231216689. PMID: 38018146

  1. Gebbia V, Martorana F, Scandurra G, Valerio MR, Cufari S, Vigneri P, Sanò MV, Scollo P.

A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy.

J Oncol Pharm Pract. 2024 Jul; 30(5):853-859. doi: 10.1177/10781552231189867. PMID: 37501558

  1. Massimino M, Stella S, Tirrò E, Pennisi MS, Stagno F, Vitale SR, Romano C, Tomarchio C, Parrinello NL, Manzella L, Di Raimondo F, Vigneri P.

High BCR-ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability.

Onco Targets Ther. 2023 Oct 3; 16:803-816. doi: 10.2147/OTT.S413825. PMID: 37807980

  1. Cipolla C, Vieni S, D’Agati E, Grassi N, Genova P, Graceffa G, Vigneri P, Gebbia V, Valerio MR.

Outcomes of Sentinel Lymph Node Biopsy for Patients with Node-positive Breast Cancer Treated with Neoadjuvant Chemotherapy.

Anticancer Res. 2023 Oct; 43(10):4643-4649. doi: 10.21873/anticanres.16659. PMID: 37772556

  1. Massimino M, Martorana F, Stella S, Vitale SR, Tomarchio C, Manzella L, Vigneri P.

Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer.

Genes (Basel). 2023 Jun 24; 14(7):1330. doi: 10.3390/genes14071330. PMID: 37510235

  1. Gebbia V, Martorana F, Scandurra G, Valerio MR, Cufari S, Vigneri P, Sanò MV, Scollo P.

A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy.

J Oncol Pharm Pract. 2023 Jul 27: 10781552231189867. doi: 10.1177/10781552231189867. PMID: 37501558

  1. Pennisi MS, Di Gregorio S, Tirrò E, Romano C, Duminuco A, Garibaldi B, Giuffrida G, Manzella L, Vigneri P, Palumbo GA.

Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports.

Hematol Rep. 2023 May 23; 15(2):317-324. doi: 10.3390/hematolrep15020033. PMID: 37367082

  1. Stella S, Massimino M, Manzella L, Parrinello NL, Vitale SR, Martorana F, Vigneri P.

Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells.

Front Endocrinol 2023 Jun 9; 14:1081831. doi: 10.3389/fendo.2023.1081831. PMID: 37361518

  1. Migliore M, Fiore M, Filippini T, Tumino R, Sabbioni M, Spatola C, Polosa R, Vigneri P, Nardini M, Castorina S, Basile F, Ferrante M; University of Catania Study Group of Malignant Pleural Mesotelioma.

Comparison of video-assisted pleurectomy/decortication surgery plus hyperthermic intrathoracic chemotherapy with VATS talc pleurodesis for the treatment of malignant pleural mesothelioma: A pilot study.

Heliyon. 2023 May 25; 9(6):e16685. doi: 10.1016/j.heliyon.2023.e16685. PMID: 37292347

  1. Gebbia V, Valerio MR, Martorana F, Sanò MV, Vigneri P.

Letter to the Editor: statistics and clinical perception of patients’ reported outcomes for palbociclib and abemaciclib: a sliding doors story.

J Comp Eff Res. 2023 Jun; 12(6):e220212. doi: 10.57264/cer-2022-0212. PMID: 37114420

  1. Stella S, Martorana F, Massimino M, Vitale SR, Manzella L, Vigneri P.

Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far.

Onco Targets Ther. 2023 Apr 7; 16:235-247. doi: 10.2147/OTT.S379867. PMID: 37056632

  • Veschi V, Turdo A, Modica C, Verona F, Di Franco S, Gaggianesi M, Tirrò E, Di Bella S, Iacono ML, Pantina VD, Porcelli G, Mangiapane LR, Bianca P, Rizzo A, Sciacca E, Pillitteri I, Vella V, Belfiore A, Bongiorno MR, Pistone G, Memeo L, Colarossi L, Giuffrida D, Colarossi C, Vigneri P, Todaro M, Stassi G.

Recapitulating thyroid cancer histotypes through engineering embryonic stem cells.

Nat Commun. 2023 Mar 11; 14(1):1351. doi: 10.1038/s41467-023-36922-1. PMID: 36906579

  • Gebbia V, Martorana F, Sanò MV, Valerio MR, Giotta F, Spada M, Piazza D, Caruso M, Vigneri P.

Abemaciclib-associated Diarrhea: An Exploratory Analysis of Real-life Data.

Anticancer Res. 2023 Mar; 43(3):1291-1299. doi: 10.21873/anticanres.16276. PMID: 36854501

  • Lorenzo R, Meani F, Longhitano C, Carciotto R, Lanzafame K, Inzerilli N, Vigneri P.

The optimal timing between neoadjuvant therapy and surgery of breast cancer: a brief systematic review of the literature.

Crit Rev Oncol Hematol. 2023 Feb 4: 103921. doi: 10.1016/j.critrevonc.2023.103921. PMID: 36746358

  • Buono G, Arpino G, Del Mastro L, Fabi A, Generali D, Puglisi F, Zambelli A, Cinieri S, Nuzzo F, Di Lauro V, Vigneri P, Bianchini G, Montemurro F, Gennari A, De Laurentiis M.

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice.

Front Oncol. 2022 Oct 26; 12:1032166. doi: 10.3389/fonc.2022.1032166. PMID: 36387212

  • Fabi A, Buono G, Bria E, Bianchini G, Curigliano G, De Laurentiis M, De Placido S, Del Mastro L, Guarneri V, Generali D, Livi L, Lorusso V, Montemurro F, Puglisi F, Vigneri P, Zambelli A, Arpino G.

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach.

Front Oncol. 2022 Sep 9; 12:950861. doi: 10.3389/fonc.2022.950861. PMID: 36158652

  • Pavone G, Romano C, Martorana F, Motta L, Salvatorelli L, Zanghì AM, Magro G, Vigneri P.

Giant Paratesticular Liposarcoma: Molecular Characterization and Management Principles with a Review of the Literature.

Diagnostics (Basel). 2022 Sep 6; 12(9):2160. doi: 10.3390/diagnostics12092160. PMID: 36140560

  • Ieni A, Pizzimenti C, Broggi G, Caltabiano R, Germanò A, Barbagallo GMV, Vigneri P, Giuffrè G, Tuccari G.

Immunoexpression of p62/SQSTM1/Sequestosome-1 in human primary and recurrent IDH1/2 wild-type glioblastoma: A pilot study.

Oncol Lett. 2022 Aug 11;24(4):336. doi: 10.3892/ol.2022.13456. PMID: 36039055

  • Malaguarnera R, Gabriele C, Santamaria G, Giuliano M, Vella V, Massimino M, Vigneri P, Cuda G, Gaspari M, Belfiore A.

Comparative proteomic analysis of insulin receptor isoform A and B signaling.

Mol Cell Endocrinol. 2022 Aug 5; 557:111739. doi: 10.1016/j.mce.2022.111739. PMID: 35940390

  • Stella S, Vitale SR, Massimino M, Motta G, Longhitano C, Lanzafame K, Martorana F, Fazzari C, Vecchio GM, Tirrò E, Inzerilli N, Carciotto R, Manzella L, Caruso M, Vigneri P.

Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer.

Cancer Genomics Proteomics. 2022 Jul-Aug;19(4):464-476. doi: 10.21873/cgp.20333. PMID: 35732329

  • Romano C, Di Gregorio S, Pennisi MS, Tirrò E, Broggi G, Caltabiano R, Manzella L, Ruggieri M, Vigneri P, Di Cataldo A.

Multiple primary malignances managed with surgical excision: a case report with next generation sequencing analysis. Mol Biol Rep. 2022 Jun 17. doi: 10.1007/s11033-022-07630-8. PMID: 35715605

  • Sapuppo G, Martorana F, Tirrò E, Le Moli R, Masucci R, Baldeschi L, Spatola C, Belfiore A, Vigneri P, Pellegriti G.

Orbital metastasis from thyroid cancer: a case report and review of the literature.

Ann Palliat Med. 2022 Jun 2:apm-22-61. doi: 10.21037/apm-22-61. PMID: 35695049

  • Salmon M, White HE, Zizkova H, Gottschalk A, Motlova E, Cerveira N, Colomer D, Coriu D, Franke GN, Gottardi E, Izzo B, Jurcek T, Lion T, Schäfer V, Venturi C, Vigneri P, Zawada M, Zuna J, Hovorkova L, Koblihova J, Klamova H, Markova MS, Srbova D, Benesova A, Polivkova V, Zackova D, Mayer J, Roeder I, Glauche I, Ernst T, Hochhaus A, Polakova KM, Cross NCP.

Impact of BCR-ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. Leukemia. 2022 Jul;36(7):1879-1886. doi: 10.1038/s41375-022-01612-2. PMID: 35676453

  • White HE, Salmon M, Albano F, Andersen CSA, Balabanov S, Balatzenko G, Barbany G, Cayuela JM, Cerveira N, Cochaux P, Colomer D, Coriu D, Diamond J, Dietz C, Dulucq S, Engvall M, Franke GN, Gineikiene-Valentine E, Gniot M, Gómez-Casares MT, Gottardi E, Hayden C, Hayette S, Hedblom A, Ilea A, Izzo B, Jiménez-Velasco A, Jurcek T, Kairisto V, Langabeer SE, Lion T, Meggyesi N, Mešanović S, Mihok L, Mitterbauer-Hohendanner G, Moeckel S, Naumann N, Nibourel O, Oppliger Leibundgut E, Panayiotidis P, Podgornik H, Pott C, Rapado I, Rose SJ, Schäfer V, Touloumenidou T, Veigaard C, Venniker-Punt B, Venturi C, Vigneri P, Vorkinn I, Wilkinson E, Zadro R, Zawada M, Zizkova H, Müller MC, Saussele S, Ernst T, Machova Polakova K, Hochhaus A, Cross NCP.

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.

Leukemia. 2022 May 25. doi: 10.1038/s41375-022-01607-z. PMID: 35614319

  • Massimino M, Stella S, Micale G, Motta L, Pavone G, Broggi G, Piombino E, Magro G, Soto Parra HJ, Manzella L, Vigneri P.

Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions. Cancer Genomics Proteomics. May-Jun 2022; 19(3):350-361. doi: 10.21873/cgp.20325.

  • Tirrò E, Massimino M, Broggi G, Romano C, Minasi S, Gianno F, Antonelli M, Motta G, Certo F, Altieri R, Manzella L, Caltabiano R, Barbagallo GMV, Buttarelli FR, Magro G, Giangaspero F, Vigneri P.

A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients with Diffuse Gliomas: Diagnostic and Therapeutic Applications.

Front Oncol. 2022 Mar 17; 12:861078. doi: 10.3389/fonc.2022.861078.

  • Failla M, Caltabiano R, Longo A, Russo A, Reibaldi M, Avitabile T, Piombino E, Colarossi C, Colarossi L, Tirrò E, Vigneri P, Foti PV, Broggi G.

A Case of Non-Irradiated Balloon Cell Melanoma of the Choroid: Expanding the Morphological Spectrum of Primary Uveal Melanomas.

Diagnostics (Basel). 2022 Mar 5;12(3):642. doi: 10.3390/diagnostics12030642.

  • Sanò MV, Martorana F, Lavenia G, Rossello R, Prestifilippo A, Sava S, Ricciardi GR, Vigneri P.

Ribociclib efficacy in special populations and analysis of patient reported outcomes in the MONALEESA trials.

Expert Rev Anticancer Ther. 2022 Mar 18. doi: 10.1080/14737140.2022.2052277. PMID: 35303782

  • Tirrò E, Martorana F, Micale G, Inzerilli N, Carciotto R, Romano C, Longhitano C, Motta G, Lanzafame K, Stella S, Massimino M, Vitale SR, Salvatorelli L, Magro G, Manzella L, Vigneri P.

Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience.

Pathol Res Pract. 2022 Feb 25; 232:153820. doi: 10.1016/j.prp.2022.153820. PMID: 35240549

  • Broggi G, Piombino E, Altieri R, Romano C, Certo F, Barbagallo GMV, Vigneri P, Condorelli D, Colarossi L, Colarossi C, Magro G, Tirrò E.

Glioblastoma, IDH-Wild Type with FGFR3-TACC3 Fusion: When Morphology May Reliably Predict the Molecular Profile of a Tumor. A Case Report and Literature Review.

Front Neurol. 2022 Feb 9; 13:823015. doi: 10.3389/fneur.2022.823015. PMID: 35222252

  • Angelico G, Marletta S, Broggi G, Vigneri P, Vecchio GM, Salvatorelli L, Magro G.

Practical Approach to the Diagnosis of the Vulvo-Vaginal Stromal Tumors: an Overview.

Diagnostics (Basel). 2022 Jan 31; 12(2):357. doi: 10.3390/diagnostics12020357. PMID: 35204448

  • Vitale SR, Ruigrok-Ritstier K, Timmermans AM, Foekens R, Trapman-Jansen AMAC, Beaufort CM, Vigneri P, Sleijfer S, Martens JWM, Sieuwerts AM, Jansen MPHM.

The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer.

BMC Cancer. 2022 Feb 12; 22(1):165. doi: 10.1186/s12885-022-09265-1. PMID: 35151276

  • Broggi G, Tirrò E, Alzoubi H, Arcella A, Gianno F, Antonelli M, Minasi S, Vigneri P, Certo F, Altieri R, Barbagallo GMV, Miele E, Caltabiano R, Giangaspero F.

Cerebellar liponeurocytoma: clinical, histopathological and molecular features of a series of three cases, including one recurrent tumor.

Neuropathology. 2022 Jan 18. doi: 10.1111/neup.12799. Online ahead of print. PMID: 35042275

  • Foti PV, Inì C, Broggi G, Farina R, Palmucci S, Spatola C, Liardo RLE, Milazzotto R, Raffaele L, Salamone V, Caltabiano R, Puzzo L, Russo A, Reibaldi M, Longo A, Vigneri P, Venturini M, Giurazza F, Avitabile T, Basile A.

Histopathologic and MR Imaging Appearance of Spontaneous and Radiation-Induced Necrosis in Uveal Melanomas: Initial Results.

Cancers (Basel). 2022 Jan 2; 14(1):215. doi: 10.3390/cancers14010215. PMID: 35008378

  • Pavone G, Motta L, Martorana F, Motta G, Vigneri P.

A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors.

Molecules. 2021 Dec 1; 26(23):7294. doi: 10.3390/molecules26237294. PMID: 34885875

  • Massimino M, Vigneri P, Stella S, Tirrò E, Pennisi MS, Parrinello LN, Vetro C, Manzella L, Stagno F, Di Raimondo F.

Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but does not Eradicate the Primitive Leukemic Cells.

J Clin Med. 2021 Nov 29; 10(23):5606. doi: 10.3390/jcm10235606. PMID: 34884309

  • Valerio MR, Spadaro P, Arcanà C, Borsellino N, Cipolla C, Vigneri P, Piazza D, Gebbia V.

Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis.

Future Sci OA. 2021 Nov 12; 7(10):FSO750. doi: 10.2144/fsoa-2020-0095. PMID: 34840807

  • Vella V, Giuliano M, La Ferlita A, Pellegrino M, Gaudenzi G, Alaimo S, Massimino M, Pulvirenti A, Dicitore A, Vigneri P, Vitale G, Malaguarnera R, Morrione A, Sims AH, Ferro A, Maggiolini M, Lappano R, De Francesco EM, Belfiore A.

Novel Mechanisms of Tumor Promotion by the Insulin Receptor Isoform A in Triple-Negative Breast Cancer Cells.

Cells. 2021 Nov 12; 10(11):3145. doi: 10.3390/cells10113145. PMID: 34831367

  • Massimino M, Sciacca L, Parrinello NL, Scalisi NM, Belfiore A, Vigneri R, Vigneri P.

Insulin Receptor Isoforms Differently Regulate Cell Proliferation and Apoptosis in the Ligand-Occupied and Unoccupied State.

Int J Mol Sci. 2021 Aug 13; 22(16):8729. doi: 10.3390/ijms22168729. PMID: 34445431

  • Gianì F, Masto R, Trovato MA, Malandrino P, Russo M, Pellegriti G, Vigneri P, Vigneri R.

Heavy Metals in the Environment and Thyroid Cancer.

Cancers (Basel). 2021 Aug 12; 13(16):4052. doi: 10.3390/cancers13164052. PMID: 34439207

  • Di Franco S, Bianca P, Sardina DS, Turdo A, Gaggianesi M, Veschi V, Nicotra A, Mangiapane LR, Lo Iacono M, Pillitteri I, van Hooff S, Martorana F, Motta G, Gulotta E, Lentini VL, Martorana E, Fiori ME, Vieni S, Bongiorno MR, Giannone G, Giuffrida D, Memeo L, Colarossi L, Mare M, Vigneri P, Todaro M, De Maria R, Medema JP, Stassi G.

Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery.

Nat Commun. 2021 Aug 18; 12(1):5006. doi: 10.1038/s41467-021-25333-9. PMID: 34408135

  • Massimino M, Tirrò E, Stella S, Manzella L, Pennisi MS, Romano C, Vitale SR, Puma A, Tomarchio C, Di Gregorio S, Antolino A, Di Raimondo F, Vigneri P.

Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts.

Front Pharmacol. 2021 Jun 30; 12:669469. doi: 10.3389/fphar.2021.669469. eCollection 2021. PMID: 34276365

  • Foti PV, Travali M, Farina R, Palmucci S, Spatola C, Raffaele L, Salamone V, Caltabiano R, Broggi G, Puzzo L, Russo A, Reibaldi M, Longo A, Vigneri P, Avitabile T, Ettorre GC, Basile A.

Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part II: MR imaging with pathologic correlation and technical considerations

Insights Imaging. 2021 Jun 4; 12(1):67. doi: 10.1186/s13244-021-01001-w.

  • Foti PV, Travali M, Farina R, Palmucci S, Spatola C, Raffaele L, Salamone V, Caltabiano R, Broggi G, Puzzo L, Russo A, Reibaldi M, Longo A, Vigneri P, Avitabile T, Ettorre GC, Basile A.

Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part I: MR imaging with pathologic correlation and technical considerations

Insights Imaging. 2021 Jun 3; 12(1):66. doi: 10.1186/s13244-021-01000-x.

  • Broggi G, Salvatorelli L, Barbagallo D, Certo F, Altieri R, Tirrò E, Massimino M, Vigneri P, Guadagno E, Maugeri G, D’Agata V, Musumeci G, Ragusa M, Barbagallo GMV, Russo D, Caltabiano R.

Diagnostic Utility of the Immunohistochemical Expression of Serine and Arginine Rich Splicing Factor 1 (SRSF1) in the Differential Diagnosis of Adult Gliomas

Cancers (Basel). 2021 Apr 26; 13(9):2086. doi: 10.3390/cancers13092086.

  • Martorana F, Motta G, Pavone G, Motta L, Stella S, Vitale SR, Manzella L, Vigneri P.

AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?

Front Pharmacol. 2021 Apr 29; 12:662232. doi: 10.3389/fphar.2021.662232.

  • Stella S, Martorana F, Manzella L, Vigneri P.

The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities

Transl Oncol. 2021 May 13; 14(8):101104. doi: 10.1016/j.tranon.2021.101104.

  • Vitale SR, Martorana F, Stella S, Motta G, Inzerilli N, Massimino M, Tirrò E, Manzella L, Vigneri P.

PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance

Crit Rev Oncol Hematol. 2021 Apr 15; 162:103334. doi: 10.1016/j.critrevonc.2021.103334.

  • Fusco N, Malapelle U, Fassan M, Marchiò C, Buglioni S, Zupo S, Criscitiello C, Vigneri P, Dei Tos AP, Maiorano E, Viale G.

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Front Oncol. 2021 Mar 25; 11:644737. doi: 10.3389/fonc.2021.644737.

  • Vitale SR, Helmijr JA, Gerritsen M, Coban H, van Dessel LF, Beije N, van der Vlugt-Daane M, Vigneri P, Sieuwerts AM, Dits N, van Royen ME, Jenster G, Sleijfer S, Lolkema M, Martens JWM, Jansen MPHM.

Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer

BMC Cancer. 2021 Mar 24; 21(1):315. doi: 10.1186/s12885-021-08007-z.

  • Martorana F, Lanzafame K, Pavone G, Motta L, Motta G, Inzerilli N, Carciotto R, Vecchio GM, Zanghì AM, Parra HJS, Magro G, Vigneri P.

Early Gastrointestinal Progression to Immunotherapy in Lung Cancer: A Report of Two Cases

Case Rep Oncol Med. 2021 Feb 26; 2021:6692538. doi: 10.1155/2021/6692538.

  • Gregorc V, Mazzarella L, Lazzari C, Graziano P, Vigneri P, Genova C, Toschi L, Ciliberto G, Bonanno L, Delmonte A, Bucci G, Rossi A, Motta G, Coco S, Marinello A, Buglioni S, Cangi MG, Di Micco C, Bandiera A, Bonfiglio S, Pecciarini L, Guida A, Ceol A, Frigè G, De Maria R, Pelicci PG.

Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung Cancer

Clin Lung Cancer. 2021 Feb 25; S1525-7304(20)30350-8. doi: 10.1016/j.cllc.2020.12.007.

  • Tirrò E, Massimino M, Romano C, Martorana F, Pennisi MS, Stella S, Pavone G, Di Gregorio S, Puma A, Tomarchio C, Vitale SR, Manzella L, Vigneri P.

Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma

Front Oncol. 2021 Feb 2; 10:612385. doi: 10.3389/fonc.2020.612385.

  • Valerio MR, Arrivas Bajardi E, Arcara CC, Borsellino N, Lo Mauro M, Cipolla C, Santarpia M, Firenze A, Motta G, Vigneri P, Gebbia V.

Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety

Am J Clin Oncol. 2021 Mar 1; 44(3):105-108. doi: 10.1097/COC.0000000000000790.

  • Stella S, Massimino M, Manzella L, Pennisi MS, Tirrò E, Romano C, Vitale SR, Puma A, Tomarchio C, Gregorio SD, Palumbo GA, Vigneri P.

Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes.

Int J Mol Sci. 2021 Jan 6; 22(2):486. doi: 10.3390/ijms22020486.

  • Certo F, Altieri R, Maione M, Schonauer C, Sortino G, Fiumanò G, Tirrò E, Massimino M, Broggi G, Vigneri P, Magro G, Visocchi M, Barbagallo GMV.

FLAIRectomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series.

Oper Neurosurg (Hagerstown). 2021 20:(2) 151-63. doi: 10.1093/ons/opaa293.

  • Gebbia V, Aiello MM, Banna G, Blanco G, Blasi L, Borsellino N, Giuffrida D, Mauro ML, Mancuso G, Piazza D, Savio G, Parra HS, Valerio MR, Verderame F, Vigneri P.

Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis.

Ecancermedicalscience. 2020 Sep 29; 14:1113. doi: 10.3332/ecancer.2020.1113.

  • Vigneri R, Sciacca L, Vigneri P.

Rethinking the Relationship between Insulin and Cancer.

Trends Endocrinol Metab. 2020 Aug; 31(8):551-560. doi: 10.1016/j.tem.2020.05.004.

  • Silvestri G, Trotta R, Stramucci L, Ellis JJ, Harb JG, Neviani P, Wang S, Eisfeld AK, Walker CJ, Zhang B, Srutova K, Gambacorti-Passerini C, Pineda G, Jamieson CHM, Stagno F, Vigneri P, Nteliopoulos G, May PC, Reid AG, Garzon R, Roy DC, Moutuou MM, Guimond M, Hokland P, Deininger MW, Fitzgerald G, Harman C, Dazzi F, Milojkovic D, Apperley JF, Marcucci G, Qi J, Polakova KM, Zou Y, Fan X, Baer MR, Calabretta B, Perrotti D.

Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions.

Blood Cancer Discov. 2020 Jul; 1(1):48-67. doi: 10.1158/0008-5472.BCD-19-0039.

  • Gebbia V, Valerio MR, Firenze A, Vigneri P.

Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor.

Expert Opin Drug Saf. 2020 Jun 22:1-9. doi: 10.1080/14740338.2020.1781814.

  • Malandrino P, Russo M, Gianì F, Pellegriti G, Vigneri P, Belfiore A, Rizzarelli E, Vigneri R.

Increased Thyroid Cancer Incidence in Volcanic Areas: A Role of Increased Heavy Metals in the Environment?

Int J Mol Sci. 2020 May 12; 21(10):3425. doi: 10.3390/ijms21103425.

  • Soverini S, Bavaro L, De Benedittis C, Martelli M, Iurlo A, Orofino N, Sica S, Sorà F, Lunghi F, Ciceri F, Galimberti S, Baratè C, Bonifacio M, Scaffidi L, Castagnetti F, Gugliotta G, Albano F, Russo Rossi AV, Stagno F, di Raimondo F, D’Adda M, di Bona E, Abruzzese E, Binotto G, Sancetta R, Salvucci M, Capodanno I, Girasoli M, Coluzzi S, Attolico I, Musolino C, Calistri E, Annunziata M, Bocchia M, Stella S, Serra A, Errichiello S, Saglio G, Pane F, Vigneri P, Mignone F, Laginestra MA, Pileri SA, Percesepe A, Tenti E, Rosti G, Baccarani M, Cavo M, Martinelli G.

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.

Blood. 2020 Feb 20; 135(8):534-541. doi: 10.1182/blood.2019002969.

  • Malandrino P, Russo M, Ronchi A, Moretti F, Gianì F, Vigneri P, Masucci R, Pellegriti G, Belfiore A, Vigneri R.

Concentration of Metals and Trace Elements in the Normal Human and Rat Thyroid: Comparison with Muscle and Adipose Tissue and Volcanic Versus Control Areas.

Thyroid. 2020 Feb; 30(2):290-299. doi: 10.1089/thy.2019.0244.

  • Martorana F, Vigneri P, Manzella L, Tirrò E, Soto Parra HJ.

Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma.

Future Oncol. 2020 Jan; 16(1s):9-13. doi: 10.2217/fon-2019-0596.

  • Baccarani M, Abruzzese E, Accurso V, Albano F, Annunziata M, Barulli S, Beltrami G, Bergamaschi M, Binotto G, Bocchia M, Caocci G, Capodanno I, Cavazzini F, Cedrone M, Cerrano M, Crugnola M, D’Adda M, Elena C, Fava C, Fazi P, Fozza C, Galimberti S, Giai V, Gozzini A, Gugliotta G, Iurlo A, La Barba G, Levato L, Lucchesi A, Luciano L, Lunghi F, Lunghi M, Malagola M, Marasca R, Martino B, Melpignano A, Miggiano MC, Montefusco E, Musolino C, Palmieri F, Pregno P, Rapezzi D, Rege-Cambrin G, Rupoli S, Salvucci M, Sancetta R, Sica S, Spadano R, Stagno F, Tiribelli M, Tomassetti S, Trabacchi E, Bonifacio M, Breccia M, Castagnetti F, Pane F, Russo D, Saglio G, Soverini S, Vigneri P, Rosti G.

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.

Blood Adv. 2019 Dec 23; 3(24):4280-4290. doi: 10.1182/bloodadvances.2019000865.

  • Stella S, Gottardi EM, Favout V, Barragan Gonzalez E, Errichiello S, Vitale SR, Fava C, Luciano L, Stagno F, Grimaldi F, Pironi L, Sargas Simarro C, Vigneri P, Izzo B.

The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias.

Int J Mol Sci. 2019 Dec 4; 20(24):6106. doi: 10.3390/ijms20246106. PMID: 31817063

  • Soverini S, Abruzzese E, Bocchia M, Bonifacio M, Galimberti S, Gozzini A, Iurlo A, Luciano L, Pregno P, Rosti G, Saglio G, Stagno F, Tiribelli M, Vigneri P, Barosi G, Breccia M.

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper

J Hematol Oncol. 2019 Dec 5; 12(1):131. doi: 10.1186/s13045-019-0815-5. PMID: 31801582

  • Motta G, Vigneri P.

Current strategies incorporating immune checkpoint inhibitors for the treatment of advanced or metastatic non-small-cell lung cancers.

Future Oncol. 2019 Sep 15; (27):3097-101. doi: 10.2217/fon-2018-0119.

  • Tirrò E, Martorana F, Romano C, Vitale SR, Motta G, Di Gregorio S, Massimino M, Pennisi MS, Stella S, Puma A, Gianì F, Russo M, Manzella L, Vigneri P.

Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.

Genes 2019 Sep 13; 10(9). pii: E709. doi: 10.3390/genes10090709.

  • Pennisi MS, Stella S, Vitale SR, Puma A, Di Gregorio S, Romano C, Tirrò E, Massimino M, Antolino A, Siragusa S, Mannina D, Impera S, Musolino C, Mineo G, Martino B, Zammit V, Di Raimondo F, Manzella L, Stagno F, Vigneri P.

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors.

Front Oncol. 2019 Aug 13; 9:764. doi: 10.3389/fonc.2019.00764.

  • Manzella L, Massimino M, Stella S, Tirrò E, Pennisi MS, Martorana F, Motta G, Vitale SR, Puma A, Romano C, Di Gregorio S, Russo M, Malandrino P, Vigneri P.

Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment.

Int J Mol Sci. 2019 Jul 2; 20(13). pii: E3258. doi: 10.3390/ijms20133258.

  • Gianì F, Pandini G, Scalisi NM, Vigneri P, Fazzari C, Malandrino P, Russo M, Masucci R, Belfiore A, Pellegriti G, Vigneri R.

Effect of low-dose tungsten on human thyroid stem/precursor cells and their progeny.

Endocr Relat Cancer. 2019 May 1. pii: ERC-19-0176.R1. doi: 10.1530/ERC-19-0176.

  • Stella S, Zammit V, Vitale SR, Pennisi MS, Massimino M, Tirrò E, Forte S, Spitaleri A, Antolino A, Siracusa S, Accurso V, Mannina D, Impera S, Musolino C, Russo S, Malato A, Mineo G, Musso M, Porretto F, Martino B, Di Raimondo F, Manzella L, Vigneri P, Stagno F.

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.

Int J Mol Sci. 2019 May 6; 20(9). pii: E2226. doi: 10.3390/ijms20092226.

  • Tirrò E, Massimino M, Romano C, Pennisi MS, Stella S, Vitale SR, Fidilio A, Manzella L, Parrinello NL, Stagno F, Palumbo GA, La Cava P, Romano A, Di Raimondo F, Vigneri PG.

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53.

Front Oncol. 2019 Feb 18; 9:57. doi: 10.3389/fonc.2019.00057. eCollection 2019.

  • Vella V, Milluzzo A, Scalisi NM, Vigneri P, Sciacca L.

Insulin Receptor Isoforms in Cancer.

Int J Mol Sci. 2018 Nov 16; 19(11). pii: E3615. doi: 10.3390/ijms19113615.

  • Pirosa MC, Leotta S, Cupri A, Stella S, Martino EA, Scalise L, Sapienza G, Calafiore V, Mauro E, Spadaro A, Vigneri P, Di Raimondo F, Milone G.

Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph’+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.

Chemotherapy. 2018 63(4):220-224. doi: 10.1159/000492941. Epub 2018 Oct 29.

  • Vitale SR, Sieuwerts AM, Beije N, Kraan J, Angus L, Mostert B, Reijm EA, Van NM, van Marion R, Dirix LY, Hamberg P, de Jongh FE, Jager A, Foekens JA, Vigneri P, Sleijfer S, Jansen MPHM, Martens JWM.

An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA.

J Mol Diagn. 2019 Jan; 21(1):123-137. doi: 10.1016/j.jmoldx.2018.08.010. Epub 2018 Oct 6.

  • Vella V, Nicolosi ML, Cantafio P, Massimino M, Lappano R, Vigneri P, Ciuni R, Gangemi P, Morrione A, Malaguarnera R, Belfiore A.

DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop.

Endocr Relat Cancer. 2019 Jan 1; 26(1):197-214. doi: 10.1530/ERC-18-0310.

  • Migliore M, Fornito M, Palazzolo M, Criscione A, Gangemi M, Borrata F, Vigneri P, Nardini M, Dunning J.

Ground glass opacities management in the lung cancer screening era.

Ann Transl Med. 2018 Mar; 6(5):90. doi: 10.21037/atm.2017.07.28.

  • Massimino M, Stella S, Tirrò E, Romano C, Pennisi MS, Puma A, Manzella L, Zanghì A, Stagno F, Di Raimondo F, Vigneri P.

Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.

Mol Cancer. 2018 17(1):56.

  • Tavarelli M, Malandrino P, Vigneri P, Richiusa P, Maniglia A, Violi MA, Sapuppo G, Vella V, Dardanoni G, Vigneri R, Pellegriti G.

Anaplastic Thyroid Cancer in Sicily: The Role of Environmental Characteristics.

Front Endocrinol (Lausanne). 2017 8:277.

  • Vigneri P, Stagno F, Stella S, Cupri A, Forte S, Massimino M, Antolino A, Siragusa S, Mannina D, Impera SS, Musolino C, Malato A, Mineo G, Tomaselli C, Murgano P, Musso M, Morabito F, Molica S, Martino B, Manzella L, Müller MC, Hochhaus A, Raimondo FD.

High BCR-ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib.

Clin Cancer Res. 2017 23(23):7189-7198.

  • Manzella L, Stella S, Pennisi MS, Tirrò E, Massimino M, Romano C, Puma A, Tavarelli M, Vigneri P.

New Insights in Thyroid Cancer and p53 Family Proteins.

Int J Mol Sci. 2017 18(6). pii: E1325.

  • Vella V, Malaguarnera R, Nicolosi ML, Palladino C, Spoleti C, Massimino M, Vigneri P, Purrello M, Ragusa M, Morrione A, Belfiore A.

Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells.

Oncotarget. 2017 8(26):43248-43270.

  • Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G; GIMEMA CML Working Party.

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.

Am J Hematol. 2017 92(8):797-805.

  • Banna GL, Anile G, Russo G, Vigneri P, Castaing M, Nicolosi M, Strano S, Gieri S, Spina R, Patanè D, Calcara G, Fraggetta F, Marletta F, Stefano A, Ippolito M.

Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer.

Oncology. 2017 2(1):39-47.

  • Castagnetti F, Di Raimondo F, De Vivo A, Spitaleri A, Gugliotta G, Fabbiano F, Capodanno I, Mannina D, Salvucci M, Antolino A, Marasca R, Musso M, Crugnola M, Impera S, Trabacchi E, Musolino C, Cavazzini F, Mineo G, Tosi P, Tomaselli C, Rizzo M, Siragusa S, Fogli M, Ragionieri R, Zironi A, Soverini S, Martinelli G, Cavo M, Vigneri P, Stagno F, Rosti G, Baccarani M.

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.

Am J Hematol. 2017 92(1):82-87.

  • Vigneri R, Malandrino P, Gianì F, Russo M, Vigneri P.

Heavy metals in the volcanic environment and thyroid cancer.

Mol Cell Endocrinol. 2017 457:73-80.

  • Latagliata R, Stagno F, Annunziata M, Abruzzese E, Iurlo A, Guarini A, Fava C, Gozzini A, Bonifacio M, Sorà F, Leonetti Crescenzi S, Bocchia M, Crugnola M, Castagnetti F, Capodanno I, Galimberti S, Feo C, Porrini R, Pregno P, Rizzo M, Antolino A, Mauro E, Sgherza N, Luciano L, Tiribelli M, Russo Rossi A, Trawinska M, Vigneri P, Breccia M, Rosti G, Alimena G.

Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.

Neoplasia. 2016 Sep; 18(9):536-40.

  • Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D’Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A.

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.

Oncotarget. 2016 Aug 27; 7(48):80083-80090.

  • Giallongo C, Romano A, Parrinello NL, La Cava P, Brundo MV, Bramanti V, Stagno F, Vigneri P, Chiarenza A, Palumbo GA, Tibullo D, Di Raimondo F.

Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients.

PLoS One. 2016 Jul 8; 11(7):e0158392.

  1. Stagno F, Stella S, Spitaleri A, Pennisi MS, Di Raimondo F, Vigneri P.

Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.

Expert Rev Anticancer Ther. 2016; 16(3):273-8. doi: 10.1586/14737140.2016.1151356.

  1. Manzella L, Tirrò E, Pennisi MS, Massimino M, Stella S, Romano C, Vitale SR, Vigneri P.

Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia.

Curr Cancer Drug Targets. 2016

  1. Vigneri P, Martorana F, Manzella L, Stella S.

Biomarkers and prognostic factors for malignant pleural mesothelioma.

Future Oncol. 2015; 11(24 Suppl):29-33.

  1. Vigneri PG, Tirrò E, Pennisi MS, Massimino M, Stella S, Romano C, Manzella L.

The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy.

Front Oncol. 2015; 5:230.

  1. Ishii Y, Nhiayi MK, Tse E, Cheng J, Massimino M, Durden DL, Vigneri P, Wang JY.

Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release.

PLoS One. 2015; 10(10):e0140585.

  1. Russo M, Malandrino P, Addario WP, Dardanoni G, Vigneri P, Pellegriti G, Squatrito S, Vigneri R.

Several Site-specific Cancers are Increased in the Volcanic Area in Sicily.

Anticancer Res. 2015; 35(7):3995-4001.

  1. Recchia AG, Caruso N, Bossio S, Pellicanò M, De Stefano L, Franzese S, Palummo A, Abbadessa V, Lucia E, Gentile M, Vigna E, Caracciolo C, Agostino A, Galimberti S, Levato L, Stagno F, Molica S, Martino B, Vigneri P, Di Raimondo F, Morabito F.

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myeloid Leukemia: Comparison with FISH and PCR Techniques.

PLoS One. 2015; 10(6):e0130360.

  1. Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G; F Salvi, M Pini, P Leoni, S Rupoli, P Galieni, C Bigazzi, N Cantore, F Palmieri, F Albano, A Russo Rossi, A Rambaldi, T Intermesoli, F Palandri, N Testoni, S Luatti, S Soverini, I Iacobucci, M T Bochicchio, M Apolinari, M Fogli, I Cervello, A Capucci, M Malagola, A Malpignano, M Girasoli, E Angelucci, E Usala, S Storti, E De Biasi, G Tagariello, R Sartori, F Di Raimondo, P Vigneri, S Impera, S Molica, F Lanza, C Viganò, M Grasso, D Rapezzi, F Cavazzini, A Bosi, V Santini, S F Capalbo, G Spinosa, I Pierri, M Bergamaschi, A M Carella, A Bacigalupo, A De Blasio, F Ciccone, N Di Renzo, C Musolino, S Russo, A Cortelezzi, E Morra, E M Pungolino, M Luppi, R Marasca, E M Pogliani, C Gambacorti-Passerini, L Luciano, F Ferrara, M Annunziata, G Latte, D Noli, G Rege-Cambrin, C Fava, G Semenzato, G Binotto, F Fabbiano, D Turri, S Siragusa, C Caracciolo, M Musso, F Porretto, F Aversa, M Crugnola, M Cazzola, E Orlandi, B Falini, F Falzetti, G Visani, A Isidori, G Fioritoni, R Di Lorenzo, D Vallisa, E Trabacchi, M Petrini, S Galimberti, M Pizzuti, A Zaccaria, M Salvucci, F Ronco, D Ielo, F Merli, P Avanzini, P Tosi, A Merli, P Musto, V De Stefano, S Sica, R Latagliata, P De Fabritiis, M Trawiska, I Majolino, L Pacilli, B Ronci, M Cedrone, M C Petti, F Pisani, A Tafuri, E Montefusco, F Iuliano, F Dore, S Pardini, M Bocchia, M Defina, A M Liberati, D Luzzi, M Boccadoro, D Ferrero, U Vitolo, F Gherlinzoni, E Calistri, R Fanin, G Pizzolo, V Meneghini, F Rodighiero, A D’Emilio.

Differences among young adults, adults and elderly chronic myeloid leukemia patients.

Ann Oncol. 2015 Jan; 26(1):185-192. doi: 10.1093/annonc/mdu490. Epub 2014 Oct 30. PMID: 25361995

  1. Vigneri R, Malandrino P, Vigneri P

The changing epidemiology of thyroid cancer: why is incidence increasing?

Curr Opin Oncol. 2015; 26(1):185-92

  1. Giallongo C, Parrinello N, Tibullo D, La Cava P, Romano A, Chiarenza A,Barbagallo I, Palumbo GA, Stagno F, Vigneri P, Di Raimondo F

Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.

PLoS One. 2014; 9(7):e101848

  1. Sciacca L, Cassarino MF, Genua M, Vigneri P, Giovanna Pennisi M, Malandrino P, Squatrito S, Pezzino V, Vigneri R

Biological effects of insulin and its analogs on cancer cells with different insulin family receptor expression.

J Cell Physiol. 2014; 229(11):1817-21

  1. Massimino M, Consoli ML, Mesuraca M, Stagno F, Tirrò E, Stella S, Pennisi MS, Romano C, Buffa P, Bond HM, Morrone G, Sciacca L, Di Raimondo F, Manzella L, Vigneri P

IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.

Carcinogenesis. 2014; 35(5):1132-43

  1. Breccia M, Alimena G, Baccarani M, Bocchia M, Di Raimondo F,Gambacorti-Passerini C, Gozzini A, Morra E, Pane F, Pregno P, Rege-Cambrin G,Rosti G, Specchia G, Vigneri P, Saglio G

Current management of CML patients: summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.

Crit Rev Oncol Hematol. 2014; 90(3):181-9

  1. Buffa P, Romano C, Pandini A, Massimino M, Tirrò E, Di Raimondo F, Manzella L, Fraternali F, Vigneri P

BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein.

FASEB J. 2014; 28(3):1221-36

  1. Sciacca L, Vigneri R, Tumminia A, Frasca F, Squatrito S, Frittitta L, Vigneri P

Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients.

Nutr Metab Cardiovasc Dis. 2013; 23(9):808-15

  1. Experts in Chronic Myeloid Leukemia

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Blood. 2013; 121(22):4439-42

  1. Stella S, Tirrò E, Conte E, Stagno F, Di Raimondo F, Manzella L, Vigneri P

Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs.

Mol Cancer Ther. 2013; 12(6):1085-98

  1. Vigneri R, Vigneri P, Frittitta L

Basal insulin and cardiovascular and other outcomes.

N Engl J Med. 2012; 367(18):1761-2

  1. Tiribelli M, Latagliata R, Luciano L, Castagnetti F, Gozzini A, Cambrin GR, Annunziata M, Stagno F, Pregno P, Albano F, Abruzzese E, Musto P, Montefusco E, Fava C, Fanin R, Pane F, Rosti G, Breccia M, Alimena G, Vigneri P

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.

Ann Hematol. 2012; 92(2):179-83

  1. Vicari L, Martinetti D, Buccheri S, Colarossi C, Aiello E, Stagno F, Villari L, Cavalli M, Di Raimondo F, Gulisano M, De Maria R, Vigneri P

Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocytemia and myelofibrosis patients.

Br J Haematol. 2012; 159 (2):237-40

  1. Stagno F, Vigneri P, Cupri A, Vitale SR, Di Raimondo F

Infliximab therapy in hematologic malignancies: handle with care.

Haematologica. 2012; 97(8):e26-7

  1. Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.

Hematol Oncol. 2012; 31(2):103-9

  1. Stagno F, Vigneri P, Cupri A, Stella S, Di Raimondo F

Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment.

Leuk Res. 2012; 36(9):1208-9

  1. Stagno F, Vigneri P, Di Raimondo F

Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy.

Int J Hematol. 2012; 36(9):1208-9

  1. Massimino M, Vigneri P, Fallica M, Fidilio A, Aloisi A, Frasca F, Manzella L

IRF5 promotes the proliferation of human thyroid cancer cells.

Mol Cancer. 2012; 11(1):21

  1. Stagno F, Vigneri P, Di Raimondo F

Towards a need to a “biological Sokal risk” in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia.

Leuk Res. 2012; 36(7):803

  1. Stagno F, Vigneri P, Cupri A, Vitale SR, Di Raimondo F

Diagnosis of blastic phase of chronic myeloid leukemia.

Acta Haematol. 2012; 127(4):198

  1. Stagno F, Vigneri P, Consoli ML, Cupri A, Stella S, Tambè L, Massimino M, Manzella L, Di Raimondo F

Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia.

Acta Haematol. 2012; 127(1):7-9

  1. Messina RL, Sanfilippo M, Vella V, Pandini G, Vigneri P, Nicolosi ML, Gianì F, Vigneri R, Frasca F

Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells.

Int J Cancer. 2012; 130 (10):2259-70

  1. Giallongo C, Tibullo D, La Cava P, Branca A, Parrinello N, Spina P, Stagno F, Conticello C, Chiarenza A, Vigneri P, Palumbo GA, Di Raimondo F

BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint.

Acta Haematol. 2011; 126(4):205-10

  1. Latagliata R, Breccia M, Castagnetti F, Stagno F, Luciano L, Gozzini A, Ulisciani S, Cavazzini F, Annunziata M, Sorà F, Rossi AR, Pregno P, Montefusco E, Abruzzese E, Crisà E, Musto P, Tiribelli M, Binotto G, Occhini U, Feo C, Vigneri P, Santini V, Fava C, Rosti G, Alimena G

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.

Leuk Res. 2011; 35(9):1164-9

  1. Breccia M, Latagliata R, Stagno F, Luciano L, Gozzini A, Castagnetti F, Fava C, Cavazzini F, Annunziata M, Russo Rossi A, Pregno P, Abruzzese E, Vigneri P, Rege-Cambrin G, Sica S, Pane F, Santini V, Specchia G, Rosti G, Alimena G

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.

Haematologica. 2011; 96(10):1457-61

  1. Maugeri-Saccà M, Vigneri P, De Maria R

Cancer stem cells and chemosensitivity.

Clin Cancer Res. 2011; 17(15):4942-7

  1. Breccia M, Stagno F, Gozzini A, Abruzzese E, Latagliata R, Rossi AR, Sorà F, Porrini R, Vigneri P, Trawinska M, Montefusco E, Sica S, Specchia G, Santini V, Alimena G

Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors.

Am J Hematol. 2011; 86(6):523-5

  1. Preyer M, Vigneri P, Wang JY

Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL.

PLoS One. 2011; 6(2):e17020

  1. Stagno F, Vigneri P, Di Raimondo F

Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission?

Lancet Oncol. 2011; 12(2):118.

  1. Stagno F, Vigneri P, Del Fabro V, Fidilio A, Spina P, Massimino M, Messina A, Di Raimondo F

Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia.

Acta Haematol. 2010; 124(2):103-4.

  1. Stagno F, Del Fabro V, Triolo A, Parrinello NL, Vigneri P, Di Raimondo F

Utility of flow cytometry as a screening tool for transplant donors for chronic lymphocytic leukemia.

Acta Haematol. 2010; 123(4):235-6

  1. Stagno F, Vigneri P, Del Fabro V, Stella S, Cupri A, Massimino M, Consoli C, Tambè L, Consoli ML, Antolino A, Di Raimondo F

Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.

Acta Oncol. 2010; 49(4):506-8.

  1. Breccia M, Stagno F, Vigneri P, Latagliata R, Cannella L, Del Fabro V, Di Raimondo F, Alimena G

Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up.

Am J Hematol. 2010; 85(5):375-7.

  1. D’Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, Guggino G, Meraviglia S, Caccamo N, Messina A, Salerno A, Di Raimondo F, Vigneri P, Stassi G, Fourniè JJ, Dieli F

V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.

J Immunol. 2010; 184(6):3260-8.

  1. Stagno F, Vigneri P, Del Fabro V, Stella S, Restuccia N, Giallongo C, Massimino M, Berretta S, Pennisi MS, Tibullo D, Tirrò E, Buscarino C, Messina A, Di Raimondo F

Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias.

Acta Oncol. 2010; 49(1):109-10.

  1. Stagno F, Vigneri P, Stagno F, Vigneri P, Del Fabro V, Stella S, Berretta S, Massimino M, Tirrò E, Messina A, Di Raimondo F

Uncommon long-term survival in a patient with chronic myeloid leukemia.

Acta Oncol. 2009; 48(8):1215-6.

  1. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R

Diabetes and cancer.

Endocr Relat Cancer. 2009; 16(4):1103-23.

  1. Vigneri R, Frasca F, Sciacca L, Vigneri P, Frittitta L

Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women.

J Natl Cancer Inst. 2009; 101(14):1030-1

  1. Stagno F, Vigneri P, Del Fabro V, Stella S, Massimino M, Berretta S, Cupri A, Consoli C, Messina L, Tirrò E, Messina A, Di Raimondo F

Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.

Leuk Res. 2009; 33(9):e157-8.

  1. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, Vigneri P, Nicotera P, Dyer MJ, Holyoake T, Salomoni P, Calabretta B

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.

J Clin Invest. 2009; 119(5):1109-23.

  1. Vella V, Puppin C, Damante G, Vigneri R, Sanfilippo M, Vigneri P, Tell G, Frasca F

DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells.

Int J Cancer. 2009; 124(11):2539-48.

  1. Allan EK, Hamilton A, Hatziieremia S, Zhou P, Jørgensen HG, Vigneri P, Holyoake TL

Nuclear entrapment of BCR-ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells.

Leukemia. 2009; 23(5):1006-8.

  1. Stagno F, Vigneri P, Del Fabro V, Stella S, Massimino M, Berretta S, Messina A, Di Raimondo F

Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase.

Leuk Res. 2009; 33(6):e17.

  1. Stagno F, Stella S, Berretta S, Massimino M, Antolino A, Giustolisi R, Messina A, Di Raimondo F, Vigneri P.

Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.

Leuk Res. 2008; 32(4):673-4.

  1. Buffa P, Manzella L, Consoli ML, Messina A, Vigneri P.

Modelling of the ABL and ARG proteins predicts two functionally critical regions that are natively unfolded.

Proteins. 2007; 67(1):1-11.

  1. Vicari L, Eramo A, Manzella L, Malaguarnera L, Iannolo G, Gulisano M, De Maria R, Messina A, Vigneri P.

The PU.1 transcription factor induces cyclin D2 expression in U937 cells.

Leukemia. 2006; 20(12):2208-10.

  1. Tirrò E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A and Vigneri P.

Altered expression of c-IAP1, Survivin and Smac contributes to chemotherapy resistance in thyroid cancer cells.

Cancer Res. 2006; 66(8):4263-72

  1. Frasca F, Rustighi A, Malaguarnera R, Altamura S, Vigneri P, Del Sal G, Giancotti V, Pezzino V, Vigneri R, Manfioletti G.

HMGA1 inhibits the function of p53 family members in thyroid cancer cells.

Cancer Res. 2006; 66(6):2980-9

  1. Aloisi A, Di Gregorio S, Stagno F, Guglielmo P, Mannino F, Sormani MP, Bruzzi P, Gambacorti-Passerini C, Saglio G, Venuta S, Giustolisi R, Messina A, Vigneri P.

BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of Imatinib Mesylate and Leptomycin B.

Blood 2006; 107(4):1591-98

  1. Vigneri P, Frasca F, Sciacca L, Frittitta L, Vigneri R.

Obesity and cancer.

Nutr Metab Cardiovasc Dis. 2006; 16(1):1-7.

  1. Malaguarnera R, Mandarino A, Mazzon E, Vella V, Gangemi P, Vancheri C, Vigneri P, Aloisi A, Vigneri R and Frasca F.

The p53-homologue p63 may promote thyroid cancer progression.

Endocr Relat Cancer 2005; 12(4):953-971.

  1. Frasca F, Vella V, Aloisi A, Mandarino A, Mazzon E, Vigneri R, Vigneri P.

p73 tumor-suppressor activity is impaired in human thyroid cancer.

Cancer Res. 2003; 63(18):5829-37.

  1. Vella V, Zhu J, Frasca F, Li CY, Vigneri P, Vigneri R, Wang J.Y.

Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function.

J. Biol. Chem. 2003; 278(27):25151-7.

  1. Frasca F, Vigneri P, Vella V, Vigneri R, Wang J.Y.

Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor.

Oncogene. 2001; 20(29):3845-56.

  1. Vigneri P, Wang J.Y.

Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.

Nat. Med. 2001; (2):228-34.

  1. Bunone G, Vigneri P, Mariani L, Butò S, Collini P, Pilotti S, Pierotti MA, Bongarzone I.

Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.

Am. J. Pathol. 1999; 155(6):1967-76.

  1. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, Wicker R, Chiefari E, Suarez HG, Filetti S

Iodide symporter gene expression in human thyroid tumors.

J. Clin. Endocrinol. Metab. 1998; 83(7):2493-6.

  1. Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S, Pierotti M.A.

RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features.

Clin. Cancer Res. 1998; 4(1):223-8.

  1. Pierotti MA, Vigneri P, Bongarzone I.

Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas.

Recent Results Cancer Res. 1998; 154:237-47. doi: 10.1007/978-3-642-46870-4_15. PMID: 10027004

  1. Pilotti S, Collini P, Mariani L, Placucci M, Bongarzone I, Vigneri P, Cipriani S, Falcetta F, Miceli R, Pierotti MA, Rilke F.

Insular carcinoma: a distinct de novo entity among follicular carcinomas of the thyroid gland.

Am. J. Surg. Pathol. 1997; 21(12):1466-73.

  1. Russo D, Tumino S, Arturi F, Vigneri P, Grasso G, Pontecorvi A, Filetti S, Belfiore A.

Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma.

J. Clin. Endocrinol. Metab. 1997; 82(3):735-8.

  1. Belfiore A, Costantino A, Frasca F, Pandini G, Mineo R, Vigneri P, Maddux B, Goldfine ID, Vigneri R.

Overexpression of membrane glycoprotein PC-1 in MDA-MB231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity.

Mol. Endocrinol. 1996; 10(11):1318-26.

  1. Bongarzone I, Fugazzola L, Vigneri P, Mariani L, Mondellini P, Pacini F, Basolo F, Pinchera A, Pilotti S, Pierotti M.A.

Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma.

J. Clin. Endocrinol. Metab. 1996; 81(5):2006-9.

Unità

Oncologia Medica Universitaria

Torna su